Objectives. To analyse long-term survival and efficacy of TNFi, reasons for switching or discontinuing, baseline predictors of response and remission in axial spondyloarthritis (axSpA) patients in a UK cohort.
Introduction
TNFi have revolutionized the treatment of axial spondyloarthritis (axSpA), including both patients diagnosed with AS and patients diagnosed with non-radiographic axial spondyloarthritis (nr-axSpA). Efficacy has been demonstrated in randomized controlled clinical trials (RCTs) and registry studies [13] . To-date, no head-tohead RCTs of TNFi have been undertaken and no statistically significant differences in efficacy observed between individual TNFi in registry studies. It has been reported that up to one-third of patients stop their index biologic in the first year [4, 5] ; therefore, switching TNFi therapy has become established practice, which is supported by efficacy data from registry studies [3, 6, 7] .
Several studies have attempted to seek predictors for TNFi response and the longevity of TNFi therapy (drug survival). Younger age, male sex, high baseline BASDAI, low baseline BASFI, high CRP and HLA-B27 have been demonstrated as predictors of a good response [2, 4, 810] . Predictors for increased TNFi drug survival include male sex, lower BASDAI, lower BASFI and high CRP [4, 9] . The reasons for discontinuing TNFi and predictors of needing to switch are still unclear.
Reasons for TNFi discontinuation can broadly be summarized as adverse events (AEs) or inadequate response. Inadequate response is defined as primary or secondary, where primary loss of response (PLR) is a complete lack of response from initiation and secondary loss of response (SLR) is loss of response following an initial response. This differentiation may influence the choice of sequential biologic therapy. Previous studies have attempted to address how effective sequential TNFi therapies are in axSpA [11, 12] . Analysis of AS patients in Randomised Phase 3 double-blind study assessing certolizumab pegol in axial spondyloarthritis (RAPID-axSpA) found similar efficacy in patients with prior TNFi treatment and those who were TNFi-naive [13] . Furthermore, there is a lack of understanding regarding the clinical phenotype of patients who respond best to sequential TNFi. This information has assumed greater importance given the availability of biosimilars and IL-17 inhibitors, as there is considerable financial pressure to choose the most cost-effective therapy and avoid cycling through TNFi [14] .
The aims of this study were to analyse long-term survival and efficacy of TNFi, reasons for switching or discontinuing, and baseline predictors of response in a real-life UK cohort.
Methods

Patients
Adult patients commencing biologics with a physicianverified diagnosis of active axSpA (AS n = 611, 94%; nraxSpA n = 40, 6%) as defined by the National Institute for Health and Care Excellence (NICE) eligibility criteria for TNFi [15] [15] .
Drug survival and switching
The first TNFi administered was recorded as the index TNFi. Drug survival is defined as the time from initiation to permanent discontinuation of the TNFi drug. The number of years individual patients remained on TNFi treatment was used to estimate drug survival. The reasons for switching or discontinuing TNFi were recorded as AEs, PLR or SLR. We defined a flare as a two or more point or 50% increase in BASDAI 6 weeks apart in the absence of other explanations for worsening symptoms. Patients who did not fulfil the criteria were not switched to another TNFi so as to avoid switching during a temporary flare.
Disease activity and clinical response
BASDAI was recorded at baseline and then reassessed after 36 months of therapy. Response was defined as a 50% or two or more point reduction of pre-treatment BASDAI by 6 months. Low disease activity (LDA) and remission were defined as BASDAI < 3 and BASDAI < 1, respectively [16] .
Ethics
There is no formal requirement for clinical databases to apply for ethical review under NHS research governance systems, and therefore analysis of anonymized data did not require ethical approval.
Statistical analysis
Statistical analysis was undertaken using SPSS Statistics v. 22.0 (IBM Corp., Armonk, NY, USA). Predictors of treatment response, remission and drug survival were identified. Nonparametric testing, including MannWhitney and chi-square, was used to compare between groups, Wilcoxon's signedrank test for comparison within the group. KaplanMeier plots and log-rank tests were used to analyse drug survival. Cox proportional hazard and logistic regression analyses were used to assess predictors of survival and treatment response, respectively. Drug survival in the unadjusted model was performed without adjusting for confounders; multivariable models were used when adjusted for age, sex, date of symptom onset, date of diagnosis, HLA-B27, smoking history and presence of EAMs (AAU, psoriasis and IBD). P < 0.05 was considered statistically significant.
Results
Baseline characteristics
Results are reported as means (S.D.). A total of 651 patients treated with index TNFi were included in the analysis, 501 (77%) male. Of 557 available results for HLA-B27, 433 (78%) were positive. Mean age at symptom onset was 23.5 (9.2) years, mean age at diagnosis was 32.5 (11.9) years and mean age at TNFi initiation was 44.8 (12.9) years. Mean duration from symptom onset to time of diagnosis was 8.6 (8.7) years and mean duration from diagnosis to TNFi initiation was 12.6 (11.5) years.
Index TNFi were adalimumab (n = 332, 51%), etanercept (n = 205, 31%), infliximab (n = 51, 8%), golimumab (n = 40, 6%) and certolizumab pegol (n = 23, 4% Forty-seven of 105 (44.8%) patients stopped the second TNFi; the main reason for stopping was PLR (14/47, 29.8%). Of the 12/651 (1.8%) patients who commenced a third TNFi, half (6/12, 50%) stopped the third TNFi; the main reason for stopping was PLR (4/6, 66.6%).
Drug survival
Unadjusted survival rates for index TNFi at 1, 5 and 10 years were 83% (n = 499), 65% (n = 214) and 51% (n = 42), respectively, and for second TNFi at 1 and 5 years 72% (n = 72) and 52% (n = 28), respectively.
Median drug survival duration for index TNFi was 10.2 years (95% CI: 8.8, 11.6 years), which was superior to second TNFi (5.5 years, 95% CI: 2.7, 8.3 years) (P < 0.05) (Fig. 1) . No gender (P = 0.38) or drug specific (P = 0.45) differences were observed for TNFi survival (Fig. 1) . HLA-B27 positive status predicted improved drug survival (hazard ratio = 1.76, 95% CI: 1.07, 2.89) (P = 0.027).
Discussion
This is one of the largest real-life observational studies of long term TNFi in axSpA. All patients had a physicianverified diagnosis of axSpA supported by either positive radiographs (AS; 94%) or MRI (nr-axSpA; 6%). Complete data sets were available, thereby enabling us to assess response in 78% of our patients. In addition to reporting BASDAI50 and/or two or more point reduction as standard measures of efficacy, we have also reported predictors of response, survival, LDA and remission.
Index TNFi use was more effective than subsequent, which is comparable to other studies [6, 7] . In keeping with the Danish nationwide biological therapies registry (DANBIO) registry, we have also shown that patients on their index TNFi had longer drug survival than patients on second TNFi [6] . In our study, 80.5% of patients achieved a BASDAI50 and/or two or more point reduction response within 6 months. This is higher than other registries, which reported response rates between 52 and 63% [4, 5] . For BASDAI50, our response rate was 54.1%, which is consistent with other publications [2, 12] . The apparent higher response rates we observed could be explained by the fact that until 2016, TNF inhibitor eligibility, as predefined by NICE, stipulated that patients must fulfil modified New York Criteria. Our cohort, therefore, represents a welldefined sub-set of the AS clinical phenotype. Improved response rates and drug survival may therefore have been influenced by the fact that this is a well-characterized and robust cohort, for which the diagnosis has been verified by expert opinion and supported by either radiographs or MRI.
Our study is one of the first to report data on LDA [17, 18] and remission. Almost half of our patients achieved LDA and 10% achieved remission within 6 months. The concept of using the BASDAI cut-offs to define LDA and remission has been described previously [16] . Other registries have reported alternative endpoints such as the ASAS20 or ASAS40 responses, and direct comparisons with our findings are therefore not possible. We did not find any statistically significant predictors for remission; however, we identified that lower baseline BASDAI was a predictor of achieving LDA, which could be explained by the fact that patients who start with a lower BASDAI are more likely to achieve LDA. We have also shown that current and ex-smokers are less likely to achieve LDA in the first 6 months of treatment. Smoking has previously been reported to have a negative effect on disease activity [19] and TNFi efficacy [20] . Although the mechanism of the effect of smoking on TNFi remains unclear, this study supports the need to promote smoking cessation in routine clinical practice.
We found that the reason for the discontinuation of index TNFi was equally distributed between inefficacy and AEs. The switch rate in our cohort was 16.1%, which is similar to the Norwegian NOR-DMARD registry, which reported a switch rate of 14.9% among AS patients [7] , but lower than the DANBIO registry, which reported a switch rate of 30% [6] . The higher switch rate among DANBIO patients could be explained by the fact that DANBIO used physician diagnosis rather than using radiographic classification criteria for recruitment. The lower switching rate in our cohort partially reflects our high response rates but could also be related to restriction imposed by NICE guidance, whereby up until 2016, clinicians were not allowed to commence a second TNFi unless a patient had side effects to the first within the first 3 months of therapy. Of note, patients in both centres could switch via either local agreements or individual funding request applications. In addition, the lower switching rates could reflect the choice and practice of individual physicians. There are several limitations to our study; it was undertaken in two centres only, it was retrospective in design, and the choice of the TNFi treatment was physician determined. There are missing data including CRP, presence of enthesitis and peripheral arthritis, baseline MRI and concomitant DMARDs. It was therefore not possible to calculate ASAS response criteria in this study.
In conclusion, we have demonstrated good response and prolonged drug survival among axSpA patients treated with TNFi. Predictors of good response included lower baseline BASDAI, lifelong non-smoking and being HLA-B27 positive. TNFi drug survival was better in HLA-B27 positive patients and those who were TNFi-naive. Longer term studies are required to better define the predictors of TNFi response in order to select the optimum therapy, especially as biologics with an alternative mode of action are now available.
